Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCK | P35557 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.40 |
| ▸ | RAB9A | P51151 | 5/20 | 0.40 |
| ▸ | HPGD | P15428 | 5/20 | 0.40 |
| ▸ | NPC1 | O15118 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.36 |
| ▸ | MITF | O75030 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2367954 | 1.00 | GCK (0.42) | GCKSMN1; SMN2RAB9AHPGDNPC1 | |
| SCHEMBL2375628 | 0.92 | MAPK1 (0.42) | SMN1; SMN2RAB9AHPGDNPC1ALDH1A1 | |
| SCHEMBL2375624 | 0.92 | MAPK1 (0.42) | SMN1; SMN2RAB9AHPGDNPC1ALDH1A1 | |
| SCHEMBL2829876 | 0.91 | MAPK1 (0.42) | SMN1; SMN2RAB9AHPGDNPC1ALDH1A1 | |
| SCHEMBL2829873 | 0.91 | MAPK1 (0.42) | SMN1; SMN2RAB9AHPGDNPC1ALDH1A1 | |
| SCHEMBL2824729 | 0.90 | MAPK1 (0.36) | GCKSMN1; SMN2RAB9AHPGDNPC1 | |
| SCHEMBL2824727 | 0.90 | MAPK1 (0.36) | GCKSMN1; SMN2RAB9AHPGDNPC1 | |
| SCHEMBL2823652 | 0.87 | MAPT (0.42) | SMN1; SMN2HPGDALDH1A1KDM4EMITF | |
| SCHEMBL2823654 | 0.87 | MAPT (0.42) | SMN1; SMN2HPGDALDH1A1KDM4EMITF | |
| SCHEMBL13287369 | 0.86 | GCK (0.43) | GCKSMN1; SMN2RAB9AHPGDNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8318928-B2 | Fused imidazole carboxamides as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-11-27 | — | — | US | claimed |
| EP-2367825-A1 | Fused imidazole carboxamides as trpv3 modulators | Glenmark Pharmaceuticals S.A. (CH) | 2011-09-28 | — | — | EP | claimed |
| WO-2010070452-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2010-06-24 | — | — | WO | claimed |
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A (CH) | 2010-06-17 | — | — | US | claimed |
| US-8318928-B2 | Fused imidazole carboxamides as TRPV3 modulators | GLENMARK PHARMACEUTICALS, S.A. (CH) | 2012-11-27 | — | — | US | disclosed |
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | GLENMARK PHARMACEUTICALS S.A (CH) | 2010-06-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100152192-A1 | FUSED IMIDAZOLE CARBOXAMIDES AS TRPV3 MODULATORS | TRPV3, TRPV1, TRPV2 | GCK 2523/4885SMN1; SMN2 3907/4885RAB9A 2769/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.